JUDI™ to Drive Innovation and Efficiency in Pharmacy Benefit Management
NEW YORK–(BUSINESS WIRE)–Please replace the release with the following corrected version updating all instances of JUDI℠ and JUDI to JUDI™.
The updated release reads:
CAPITAL RX LAUNCHES JUDI™: THE INDUSTRY’S FIRST ENTERPRISE PHARMACY PLATFORM
JUDI™ to Drive Innovation and Efficiency in Pharmacy Benefit Management
Capital Rx, the fastest-growing pharmacy benefit manager in the U.S., announced today the launch of JUDI™, the industry’s first Enterprise Pharmacy Platform (EPP), to significantly reduce administrative overhead, advance clinical management, and radically improve customer experience in healthcare. JUDI™ was architected to unify all pharmacy benefit management (PBM) operations – from underwriting, implementation, claim adjudication, data integration, prior authorization, patient communication, client reporting, invoicing, and reimbursement – to deliver on the promise of a better care delivery system.
As the first cloud-native, self-service, end-to-end enterprise pharmacy solution ever built, JUDI™ represents a significant advancement over older adjudication systems. “The platform is entirely API based, allowing for seamless communication between existing and legacy systems,” stated Ryan Kelly, CTO of Capital Rx. “This approach allows for unlimited optionality in future integrations – the highly adaptable, configurable, and modularized framework supports all current pharmacy benefit workflows while being easily extendable to power the future of pharmacy benefits.”
The JUDI™ platform utilizes a fully serverless architecture that allows for unlimited scalability, instant right-sizing, and the unique capability to handle clients of any size. Delivered to enterprise customers in a first of its kind Platform-as-a-Service (PaaS) approach, health plans can deploy their own instance of JUDI™ in hours, not months or years.
JUDI™ was designed with simplicity and efficiency in mind, so users of all experience levels can access, edit, and update benefit plan designs quickly and easily in a single interface. The process is streamlined to ensure even the most complex plans are flawlessly implemented in a fraction of the time it would take with other PBM systems. What once took dozens of staff members weeks to complete can be done by one person in hours or minutes. “As we recently started an incredibly successful open enrollment season with our new PBM partner Capital Rx, their new JUDI™ Platform is very user friendly and easy to navigate,” said Jen Mueller, COO of Friday Health Plans. “It has been an extremely useful resource to have when assisting our members and striving to have first call resolution.”
“Launching JUDI™ is a technological leap forward, not just for pharmacy benefits, but all of healthcare,” said Matt Gibbs, the President of Commercial Markets at Capital Rx. “It is a major improvement on legacy PBM systems and our continued investment in technology will only further widen the gap.”
To learn more about JUDI™, visit www.cap-rx.com/judi. The Capital Rx mobile app can be found on the App Store and Google Play.
About Capital Rx
Capital Rx is a health technology company that manages pharmacy benefit plans for employers and health plans. With their enterprise platform, JUDI™, Capital Rx ensures patients receive seamless access to medication at the best prices by electronically linking providers, patients, pharmacies, and plans to achieve the highest standard of care. Through its Clearinghouse Model™, Capital Rx is establishing a competitive marketplace for drug pricing and redefining the way prescriptions are priced and administered in the U.S. The company’s commitment to innovation, technology, and service is why Capital Rx is the fastest-growing pharmacy benefit manager in America.
Contacts
Genevieve Pasculli
Capital Rx
Phone: +1.646.878.6902
gpasculli@cap-rx.com
Media:
Sean Leous
Westwicke/ICR PR
Phone: +1.646.677.1839
sean.leous@icrinc.com
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…
The study met its primary endpoint of overall survival with a 41% reduction in the…
DENVER, CO / ACCESSWIRE / June 15, 2024 / Each year over 120,000 Coloradans are…
REYKJAVIK, Iceland, June 15, 2024 /PRNewswire/ -- In a recent display of global baking talent,…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha-…